Loading...
•
Sep 30
Assertio Q3 2025 Earnings Report
Assertio reported its third quarter 2025 financial results, highlighting strong Rolvedon sales and progress in integration efforts.
Key Takeaways
Assertio achieved financial results in the third quarter of 2025 that position the company to meet its full-year guidance, driven by significant growth in Rolvedon net product sales and advancements in consolidating operations for greater efficiency and cost savings.
Rolvedon net product sales surged to $38.6 million, a substantial increase from $15.0 million in the prior-year quarter, partly due to advanced purchases by distributors.
The company maintained a leading market share for Rolvedon and anticipates uninterrupted patient supply, with new label sales starting in Q2 2026.
Adjusted EBITDA for Q3 2025 was $20.9 million, a significant improvement from $4.4 million in the prior-year quarter, primarily due to higher Rolvedon sales.
Assertio narrowed its full-year 2025 net product sales guidance to $110 million to $112 million and adjusted EBITDA guidance to $14 million to $16 million.
Assertio
Assertio
Assertio Revenue by Segment
Revenue by Segment
Rolvedon Net Product Sales Revenue
CapyFin.comSympazan Net Product Sales Revenue
CapyFin.comIndocin Net Product Sales Revenue
CapyFin.comNet Product Sales Revenue
CapyFin.com Forward Guidance
Assertio has narrowed its full-year 2025 guidance for Net Product Sales and Adjusted EBITDA, reflecting the impact of the Rolvedon pull-forward and increased visibility into expected performance.
Positive Outlook
- Narrowed Net Product Sales guidance range to $110 million to $112 million, indicating greater certainty.
- Narrowed Adjusted EBITDA guidance range to $14 million to $16 million, showing improved profitability outlook.
- Advanced key integration efforts to consolidate operations and align products under a single commercial entity.
- Expects greater efficiency, stronger company recognition, and ultimately cost savings from integration efforts.
- Paul Schwichtenberg promoted to President and COO, bringing extensive leadership experience to drive future growth.
Challenges Ahead
- Rolvedon demand was pulled forward by two quarters, which may impact future quarter sales patterns.
- Cash, cash equivalents, and short-term investments decreased from the prior quarter due to working capital impacts from Rolvedon sell-in.
- Expected temporary decline in cash before increasing in the second quarter of 2026 due to normalization of working capital balances.
- Indocin net product sales were down due to expected volume and pricing impacts from generic competition.
- Gross margin slightly decreased to 72% from 74% in the prior-year quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income